Anavex Life Sciences Corp. (AVXL)
NASDAQ: AVXL · Real-Time Price · USD
8.63
+0.16 (1.89%)
At close: Dec 20, 2024, 4:00 PM
8.50
-0.13 (-1.50%)
After-hours: Dec 20, 2024, 7:55 PM EST
Anavex Life Sciences Employees
Anavex Life Sciences had 40 employees as of September 30, 2023. The number of employees increased by 2 or 5.26% compared to the previous year.
Employees
40
Change (1Y)
2
Growth (1Y)
5.26%
Revenue / Employee
n/a
Profits / Employee
-$1,038,200
Market Cap
731.79M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Avanos Medical | 3,771 |
| Castle Biosciences | 610 |
| Standard BioTools | 539 |
| uniQure | 480 |
| Cronos Group | 356 |
| Relay Therapeutics | 323 |
| Kura Oncology | 142 |
| Tyra Biosciences | 49 |
AVXL News
- 5 hours ago - What To Expect in the Markets This Week - Investopedia
- 6 days ago - Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024 - GlobeNewsWire
- 13 days ago - Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer's Disease Data at J.P. Morgan 2025 Healthcare Conference - GlobeNewsWire
- 20 days ago - Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024 - GlobeNewsWire
- 26 days ago - Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer's Disease to EMA - GlobeNewsWire
- 27 days ago - Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease Journal - GlobeNewsWire
- 6 weeks ago - Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval Scenario - Seeking Alpha
- 7 weeks ago - Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024 - GlobeNewsWire